- Sophia Genetics has risen to become the global leader in precision medicine, now supporting over 100 healthcare institutions around the world to form the world’s largest clinical genomics community
- Sophia’s platform, Sophia DDM™, is a software-as-a-service platform designed to perform routine diagnostic testing, with an emphasis on genomic analysis and machine learning to help clinicians more quickly and accurately diagnose some common cancers and inherited conditions
- Sophia DDMTM enables secure knowledge sharing between clinical genomics experts, unlocking the immediate benefits of precision medicine for patients
- Since its launch in April 2014, Sophia’s cutting edge platform has supported the diagnosis of over 25,000 patients in Europe and a 80,000 patients are expected to benefit in 2016, placing Europe ahead of the US in precision medicine
LAUSANNE, Switzerland, 25 November 2015 – Sophia Genetics, the global leader in Data Driven Medicine (DDM), announced today that its platform, Sophia DDM™, now hosts the world’s largest clinical genomics community for molecular diagnosis, placing Europe ahead of the US in precision medicine. Witnessing a 400% growth rate this year alone, it now supports over 100 institutions across 18 countries, rising to become the largest network globally for interpreting pseudonymised genomics data and sharing knowledge on genomic variants clinical interpretation.
All 100 plus institutions within the community use Sophia Genetics’ cutting edge analytical solution and its advanced machine learning algorithms to analyse the genetic make-up of some common cancers and inherited conditions, such as such as cystic fibrosis, so that clinicians can more accurately diagnose patients at speed and at scale.
Speaking about this key milestone moment, Jurgi Camblong, CEO and co-founder of Sophia Genetics commented: “Over the past 18 months, Sophia Genetics’ technology has been able to make precision medicine a reality for healthcare institutions across Europe, helping patients benefit from faster and more accurate diagnosis. I am thrilled that Sophia Genetics today has been recognised as the global leader in this field, and is helping Europe lead the wider healthcare industry in delivering the value and promises associated with personalised medicine.”
The company performed over 20,000 patient analyses in 2015, and expects to quadruple this number in 2016. Users of Sophia DDM™ include Oxford University Hospitals, Hospices Civils de Lyon, Val d’Hebron Hospital and University Hospital Cologne, which leverage Sophia Genetics’ industry-leading genetic analysis technology to provide clinicians the most accurate, fast and cost-effective means to offer genomic analysis of samples to their patients.
Jurgi Camblong added: “Breaking down the information silos in healthcare, our technology acted as a real disruptor. In a spirit of crowdsourcing and sharing economy, Sophia DDM™ now allows molecular diagnosis information to be used where it is needed most, no matter where patients are treated. As we see more hospitals and labs embracing DNA Next Generation Sequencing (NGS) technics, I am particularly pleased to see Europe leading the way in the field and I look forward to welcoming more healthcare institutions on to our community platform.”
Since its inception, Sophia has built an innovative network of pioneer healthcare institutions, all leaders in their countries and eager to accelerate the routine clinical use of genomics data where they matter most first: in the clinical diagnosis setting, particularly with DNA data resulting from NGS. The community now spans 18 European countries from Spain to Poland and places Europe as a leader in precision medicine. More countries are expected to join as new hospitals and labs make use of Sophia DDM™.
